A randomised pilot study to investigate the optimum timing of gemcitabine and concurrent radiation therapy after induction gemcitabine and carboplatin for locally advanced non-small cell lung cancer
Phase 2
Active, not recruiting
- Conditions
- Advanced non-small cell lung cancerCancer - Lung - Non small cell
- Registration Number
- ACTRN12605000169640
- Lead Sponsor
- Princess Alexandra Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Active, not recruiting
- Sex
- All
- Target Recruitment
- 24
Inclusion Criteria
Histologically or cytologically proven non-small cell lung cancer.-Planned moderate dose radiation therapy for locoregional control. -Patients found to have a locally advanced thoracic disease suitable for radical therapy but on work up are found to have solitary metastasis. If in the brain the metastasis must be operable-Patients must have measurable disease on imaging scans.
Exclusion Criteria
History of any other cancer (except non-melanoma skin cancer or carcinoma in situ of the cervix) unless in complete remission and off all therapy for that cancer for at least 5 years.-Receiving treatment with another investigational agent.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Objective response rate within the irradiated volume[6 weeks post treatment and 3 monthly follow ups until death or loss to follow-up.]
- Secondary Outcome Measures
Name Time Method 1. Toxicity[];2. Progression-free survival[];3. Overall survival[]